W-18 (drug)
W-18 (drug)[edit]
W-18 is a synthetic opioid analgesic that was first synthesized in the 1980s by a team of researchers at the University of Alberta. It is part of a series of compounds known as the W-series, which were initially developed for their potential analgesic properties.
Chemical Properties[edit]
W-18 is chemically classified as a benzodiazepine derivative, although it does not exhibit the typical effects associated with benzodiazepines. The chemical structure of W-18 is characterized by a complex arrangement of atoms that contribute to its potent analgesic effects.
Pharmacology[edit]
W-18 acts on the opioid receptors in the brain, which are responsible for mediating the effects of natural and synthetic opioids. Despite its classification as an opioid, W-18 does not bind to the mu-opioid receptor in the same way as traditional opioids like morphine or fentanyl. This unique binding profile contributes to its high potency and potential for abuse.
Effects and Potency[edit]
W-18 is reported to be extremely potent, with estimates suggesting it is up to 10,000 times more potent than morphine. This high potency raises significant concerns regarding its potential for overdose and toxicity. Users may experience effects similar to other opioids, including analgesia, euphoria, and respiratory depression.
Legal Status[edit]
Due to its high potency and potential for abuse, W-18 has been classified as a controlled substance in many countries. In the United States, it is listed as a Schedule I substance under the Controlled Substances Act, indicating that it has a high potential for abuse and no accepted medical use.
Synthesis and Discovery[edit]
W-18 was first synthesized by a team led by Dr. Edward Knaus at the University of Alberta. The compound was part of a larger research effort to develop new analgesics with improved safety profiles. However, W-18 and its analogs were not pursued for clinical development due to their extreme potency and potential for harm.
